DDInter1055 DDInter907
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) downregulates {v} (Gene) SNX7
SNX7 {u} (Gene) is downregulated by {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Cisapride
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Levofloxacin {u} (Compound) downregulates {v} (Gene) SNX7
SNX7 {u} (Gene) regulates {v} (Gene) PPP2R5E
PPP2R5E {u} (Gene) is downregulated by {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) downregulates {v} (Gene) SUPV3L1
SUPV3L1 {u} (Gene) is downregulated by {v} (Compound) Sitagliptin
Sitagliptin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloperidone
Levofloxacin {u} (Compound) causes {v} (Side Effect) Diarrhoea
Diarrhoea {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Iloperidone
Levofloxacin {u} (Compound) causes {v} (Side Effect) Cataract
Cataract {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iloperidone
Levofloxacin {u} (Compound) causes {v} (Side Effect) Nystagmus
Nystagmus {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Iloperidone
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Iloperidone (Compound)
Levofloxacin (Compound) downregulates SNX7 (Gene) and SNX7 (Gene) is downregulated by Iloperidone (Compound)
Levofloxacin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Iloperidone (Compound)
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Iloperidone (Compound)
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cisapride (Compound) and Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Levofloxacin (Compound) downregulates SNX7 (Gene) and SNX7 (Gene) regulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Iloperidone (Compound)
Levofloxacin (Compound) downregulates SUPV3L1 (Gene) and SUPV3L1 (Gene) is downregulated by Sitagliptin (Compound) and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone
Levofloxacin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Iloperidone (Compound)
Levofloxacin (Compound) causes Cataract (Side Effect) and Cataract (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone
Levofloxacin (Compound) causes Nystagmus (Side Effect) and Nystagmus (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Iloperidone